The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Phase 3

Completed

Conditions: Pain
Brain and Central Nervous System Tumors
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Precancerous Condition

Interventions: Other: educational intervention
Other: questionnaire administration
Other: Titrated pain management

First Posted Date: 2008-04-24

Last Posted Date: 2012-09-06

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 98

Registration Number: NCT00666211

Locations: 🇺🇸
Erlanger Health System, Chattanooga, Tennessee, United States
🇺🇸
Tennessee Plateau Oncology, Crossville, Tennessee, United States
🇺🇸
Center for Biomedical Research, Knoxville, Tennessee, United States

and more 8 locations

Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: Docetaxel
Radiation: radiation therapy

First Posted Date: 2008-04-22

Last Posted Date: 2012-09-07

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 63

Registration Number: NCT00664105

Locations: 🇺🇸
Erlanger Health System, Chattanooga, Tennessee, United States
🇺🇸
Lehigh Valley Hospital - John & Dorothy Morgan Cancer Center, Allentown, Pennsylvania, United States
🇺🇸
The West Clinic, PC, Memphis, Tennessee, United States

and more 12 locations

Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Genetic: proteomic profiling
Procedure: lumpectomy or mastectomy
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Procedure: histopathologic examination
Procedure: magnetic resonance spectroscopy

First Posted Date: 2008-04-11

Last Posted Date: 2013-03-05

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT00656604

Investigation of Pain and Symptom Burden in Patients With Newly Diagnosed Head and Neck Cancer

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2008-04-09

Last Posted Date: 2012-09-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 100

Registration Number: NCT00655005

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Drug: celecoxib
Procedure: biopsy
Procedure: therapeutic conventional surgery

First Posted Date: 2008-04-04

Last Posted Date: 2013-05-21

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 22

Registration Number: NCT00653250

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Phase 2

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

Interventions: Drug: atrasentan hydrochloride
Drug: doxil

First Posted Date: 2008-04-04

Last Posted Date: 2012-05-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 15

Registration Number: NCT00653328

Locations: 🇺🇸
The Jones Clinic, Germantown, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Kentuckiana Cancer Institute, Louisville, Kentucky, United States

and more 3 locations

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

Early Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: letrozole
Other: Blood Collection
Procedure: biopsy/lumpectomy/mastectomy

First Posted Date: 2008-04-03

Last Posted Date: 2018-10-15

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 213

Registration Number: NCT00651976

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, One Hundred Oaks, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 2 locations

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Terminated

Conditions: Testicular Germ Cell Tumor
Breast Cancer
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Neuroblastoma
Ovarian Cancer
Multiple Myeloma and Plasma Cell Neoplasm
Gestational Trophoblastic Tumor
Myelodysplastic Syndromes

Interventions: Other: flow cytometry
Other: laboratory biomarker analysis
Other: Data Collection

First Posted Date: 2008-04-03

Last Posted Date: 2019-11-15

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 150

Registration Number: NCT00651716

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Post-operative adjuvant therapy
Drug: neoadjuvant therapy
Procedure: therapeutic surgical procedure
Radiation: Radiation therapy with concurrent Paclitaxel
Drug: Hormonal Therapy

First Posted Date: 2008-03-31

Last Posted Date: 2017-02-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 38

Registration Number: NCT00647218

Locations: 🇺🇸
Meharry Medical College, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Cetner, Nashville, Tennessee, United States
🇺🇸
Methodist Lebonheur Healthcare, Memphis, Tennessee, United States

and more 3 locations

Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: cisplatin
Drug: irinotecan hydrochloride

First Posted Date: 2008-03-20

Last Posted Date: 2012-09-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 41

Registration Number: NCT00639769

Locations: 🇺🇸
Meharry Medical College, Nashville, Tennessee, United States
🇺🇸
VA Tennessee Valley Healthcare Center, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 5 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy